News
HMD sends first shipment of 56 million syringes to Covax facility
The Hindustan Syringes & Medical Devices Ltd (HMD) has sent its first shipment of 56 million pieces of KOJAK Auto Disable Syringes to Covax facility as the race for a 'safe and effective' vaccine against coronavirus infection is on...
News
UK joins global trial to test BCG vaccine against COVID-19
A global trial, designed to test the theory that the BCG vaccine could help protect against COVID-19, will soon start recruitment in the UK.
Led by the Murdoch Children’s Research Institute (MCRI) in Melbourne, the BRACE trial started in Australia...
News
DWK Life Sciences to supply glass vials for UK vaccine development
DWK Life Sciences will provide the VMIC with borosilicate pharmaceutical glass vials which can be used to store vaccines.
The VMIC was set up to provide the UK’s first strategic vaccine development and advanced manufacturing capability and has taken a...
News
Kindred Bio Expands of Manufacturing Agreement with Vaxart for COVID-19 Vaccine
Kindred Biosciences, Inc., a biopharmaceutical company developing novel biologics, announced it has expanded an agreement with Vaxart, Inc. for the manufacture of Vaxart’s oral vaccine for COVID-19 and other vaccine candidates. The manufacturing services will be performed via Centaur...
News
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Trial
Astellas Pharma Inc. and Seagen Inc. announced positive topline results from the second cohort of patients in the pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating the antibody-drug conjugate PADCEV® (enfortumab vedotin-ejfv) for patients...
News
Merck Licenses CRISPR Genome-Editing Technology to PanCELLa and Takara Bio USA
Merck, a leading science and technology company, announced that it has signed agreements licensing its CRISPR technology to two companies — PanCELLa, a cell therapy firm based in Toronto, Canada and Takara Bio USA, Inc., a biotechnology company based...
News
Direct Biologics Granted Expanded Access by FDA for ExoFlo in the Treatment of COVID-19
Direct Biologics, LLC, announced that the FDA has granted expanded access for ExoFlo in the treatment of patients with COVID-19 associated acute respiratory distress syndrome (ARDS).
While Direct Biologics is already enrolling patients in EXIT COVID-19, its national multi-center, Phase...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















